Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-01-06
2011-11-29
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S276400
Reexamination Certificate
active
08067443
ABSTRACT:
Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
REFERENCES:
patent: 4922901 (1990-05-01), Brooks et al.
patent: 5187166 (1993-02-01), Kikuchi et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5585388 (1996-12-01), Cosford et al.
patent: 5597919 (1997-01-01), Dull et al.
patent: 5604231 (1997-02-01), Smith et al.
patent: 5616716 (1997-04-01), Dull et al.
patent: 5663356 (1997-09-01), Ruecroft et al.
patent: 5672601 (1997-09-01), Cignarella
patent: 5852041 (1998-12-01), Cosford et al.
patent: 6437138 (2002-08-01), Lin et al.
patent: 7098331 (2006-08-01), Schmitt et al.
patent: 2003/0092700 (2003-05-01), Czollner et al.
patent: 2006/0094732 (2006-05-01), Schmitt et al.
patent: 2008/0293778 (2008-11-01), Schmitt et al.
patent: 0 297 858 (1989-04-01), None
patent: 2 295 387 (1996-05-01), None
patent: WO 94/08992 (1994-04-01), None
patent: WO 96/31475 (1996-10-01), None
patent: WO 96/40682 (1996-12-01), None
patent: WO 97/46554 (1997-12-01), None
patent: WO 99/21834 (1999-05-01), None
patent: WO 00/75110 (2000-12-01), None
patent: WO 01/19817 (2001-03-01), None
patent: WO 01/32264 (2001-05-01), None
patent: WO 02/12245 (2002-02-01), None
patent: WO 03/008559 (2003-01-01), None
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Romanelli et al., Cholinergic Nicotinic Receptors: Competitive Ligands, Allosteric Modulators, and Their Potential Applications, Medicinal Research Reviews, vol. 23, No. 4, pp. 393-426, 2003.
Arneric, S., et al., “Preclinical Pharmacology of ABT-418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease,”CNS Drug Rev.1(1): 1-26 (1995).
Arneric, S., et al., “Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease,”Exp. Opin. Invest. Drugs5(1): 79-100 (1996).
Arneric et al., Neuronal nicotinic receptors: A perspective on two decades of drug discovery research, Biochemical Pharmacology 74 (2007), pp. 1092-1101.
Bannon, A. W., et al., “Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors,”Science279: 77-80 (1998).
Bencherif, M., and J. D. Schmitt, “Targeting Neuronal Nicotinic Receptors: a Path to New Therapies,”Current Drug Targets1(4): 349-357 (2002).
Bencherif, M., and R.J. Lukas, “Ligand Binding and Functional Characterization of Muscarinic Acetylcholine Receptors on the TE671/RD Human Cell Line,”J. Pharmacol. Exp. Ther.257(3): 946-953 (1991).
Bencherif, M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity I: In Vitro Characterization,”J. Pharmacol. Exper. Therapeutics279(3): 1413-1421 (1996).
Bencherif M. and R.J. Lukas, “Differential Regulation of Nicotinic Acetylcholine Receptor Expression by Human TE671/RD Cells Following Second Messenger Modulation and Sodium Butyrate Treatments,”Mol Cell Neurosci.,2(1): 52-65 (1991).
Brioni, J.D., et al., “The Pharmacology of (−)-Nicotine and Novel Cholinergic Channel Modulators,”Adv. Pharmacol.37: 153-214 (1997).
Cheng, Yung-Chi, and W.H. Prusoff, “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 Per Cent inhibition (I50) of an Enzymatic Reaction,”Biochem. Pharmacol.22(23): 3099-3108 (1973).
Chiari, A., et al., “Sex Differences in Cholinergic Analgesia I: A Supplemental Nicotinic Mechanism in Normal Females,”Anesthesiology91(5): 1447-1454 (1999).
Damaj, M.I., et al., “Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist,”J. Pharmacol. Exp. Ther.291(1): 390-398 (1999).
Damaj, M.I., et al., “Analgesic Activity of Metanicotine, A Selective Nicotinic Agonist,”Society for Neuroscience23: 669 Abstract 266.9 (1997).
Davies, Andrew R.L., et al., “Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labeling α7-type neuronal nicotinic acetylcholine receptors,”Neuropharmacol.38: 679-690 (1999).
Decina, P., et al., “Cigarette Smoking and Neuroleptic-Induced Parkinsonism,”Biol. Psychiatry,28(6): 502-508 (1990).
Gibson, S. et al., “Principal Components Describing Biological Activities and Molecular Diversity of Heterocyclic Aromatic Ring Fragments,”J. Med. Chem.,39: 4065-4072 (1996).
Hall, G.H. and D.M. Turner, “Effects of Nicotine on the Release of3H-Noradrenaline from the Hypothalamus,”Biochemical Pharmacology21: 1829-1838 (1972).
Hamon, M., “Neuropharmacology of anxiety: perspectives and prospects,”TiPS15: 36-39 (1994).
Hansch, C., et al., “The Parabolic Dependence of Drug Action upon Lipophilic Characteras Revealed by a Study of Hypnotics,”J. Med. Chem.11(1): 1-11 (1967).
Harsing, Jr., L.G., et al., “Dopamine Efflux from Striatum After Chronic Nicotine: Evidence for Autoreceptor Desensitization,”J. Neurochem.,59: 48-54 (1992).
Hery, F., et al., “Control of the Release of Newly Synthetized3H-5-Hydroxytryptamine by Nicotinic and Muscarinic Receptors in Rat Hypothalamic Slices,”Naunyn-Schmiedeberg's Arch. Pharmacol.,296: 91-97 (1977).
Holladay, M. W., et al., “Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery,”J Med. Chem40(26): 4169-4194 (1997).
Hoyer, D. and H.W.G.M. Boddeke, “Partial agonists, full agonists, antagonists: dilemmas of definition,”TiPS Reviews14: 270-275 (1993).
Lavand'homme, P., and J.C. Eisenach, “Sex Differences in Cholinergic Analgesia II: Differing Mechanisms in Two Models of Allodynia,”Anesthesiology91(5): 1455-1461 (1999).
Levin, E.D., and A.H. Rezvani, “Nicotinic Treatment for Cognitive Dysfunction,”Current Drug Targets: CNS and Neurological Disorders1(4): 423-431 (2002).
Lippiello, P.M., et al., “RJR-2403: A Nicotinic Agonist with CNS Selectivity II. In Vivo Characterization,”J. P. E. T.279(3): 1422-1429 (1996).
Lukas, R.J., and M.J. Cullen, “An Isotopic Rubidium Ion Efflux Assay for the Functional Characterization of Nicotinic Acetylcholine Receptors on Clonal Cell Lines,”Anal. Biochem.175(1): 212-218 (1988).
Lukas, R.J., “Pharmacological Distinctions between Functional Nicotinic Acetylcholine Receptors on the PC12 Rat Pheochromocytoma and the TE671 Human Medulloblastoma,”J. Pharmacol. Exp. Ther.251(1): 175-182 (1989).
Lukas R.J., et al., “Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line,”Molec Cellular Neurosci4(1): 1-12 (1993).
Luther, et al., “A Muscle Acetylcholine Receptor is Expressed in the Human Cerebellar Medulloblastoma Cell Line,”J Neurosci.9(3): 1082-1096 (1989).
Marks, M.J., et al., “Nicotinic Binding Sites in Rat and Mouse Brain: Comparison of Acetylcholine, Nicotine, and α-Bungarotoxin,”Mol. Pharmacol.30(5): 427-436 (1986).
O'Neill, M.J., et al., “The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration,
Genevois-Borella Arielle
Miller Craig H.
Fox Amy H.
Rao Deepak
Targacept, Inc.
LandOfFree
Arylvinylazacycloalkane compounds and methods of preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylvinylazacycloalkane compounds and methods of preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylvinylazacycloalkane compounds and methods of preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4276577